AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Jun 2019 07:00 AM
RNS
Lynparza nearly doubled time patients lived with
10 May 2019 07:00 AM
RNS
Pooled analyses of the roxadustat global Phase III
08 May 2019 02:00 PM
RNS
Director/PDMR Shareholding
08 May 2019 11:00 AM
RNS
Director Declaration
08 May 2019 07:00 AM
RNS
Trastuzumab deruxtecan demonstrated clinically
07 May 2019 07:00 AM
RNS
Calquence PhIII ASCEND trial met primary endpoint
03 May 2019 07:00 AM
RNS
Qternmet XR approved in the US for type-2 diabetes
01 May 2019 03:00 PM
RNS
Total Voting Rights
01 May 2019 12:00 PM
RNS
Director/PDMR Shareholding
29 Apr 2019 07:00 AM
RNS
Lynparza receives positive EU CHMP opinion for 1st
26 Apr 2019 05:45 PM
RNS
Result of AGM
26 Apr 2019 07:00 AM
RNS
AZN: Q1 2019 Results
10 Apr 2019 07:00 AM
RNS
Lynparza approved in EU for the treatment of germl
09 Apr 2019 04:10 PM
EQS
Global Pharmaceuticals: 2018 industry sales
04 Apr 2019 01:30 PM
RNS
Holding(s) in Company
03 Apr 2019 10:00 AM
RNS
Director/PDMR Shareholding
02 Apr 2019 03:00 PM
RNS
Total Voting Rights
01 Apr 2019 03:00 PM
RNS
Total Voting Rights
01 Apr 2019 07:00 AM
RNS
Selumetinib gets Breakthrough Therapy Designation
29 Mar 2019 05:15 PM
RNS
Results of Placing
29 Mar 2019 07:00 AM
RNS
AZ and Daiichi Sankyo enter collaboration in novel
29 Mar 2019 07:00 AM
RNS
Proposed placing of new ordinary shares
27 Mar 2019 07:00 AM
RNS
Forxiga approved in Japan for type-1 diabetes
25 Mar 2019 07:00 AM
RNS
Forxiga approved in Europe for type-1 diabetes
18 Mar 2019 07:00 AM
RNS
US FDA grants saracatinib ODD for IPF
14 Mar 2019 12:00 PM
RNS
Notice of AGM
12 Mar 2019 12:00 PM
RNS
Director/PDMR Shareholding
06 Mar 2019 07:00 AM
RNS
Filing of Form 20-F with SEC
05 Mar 2019 11:00 AM
RNS
Annual Financial Report
01 Mar 2019 03:00 PM
RNS
Total Voting Rights
01 Mar 2019 01:45 PM
RNS
Lynparza receives positive EU CHMP opinion
26 Feb 2019 07:00 AM
RNS
Lynparza significantly delayed disease progression
25 Feb 2019 07:00 AM
RNS
Brilinta's PhIII THEMIS trial met primary endpoint
14 Feb 2019 07:00 AM
RNS
AstraZeneca Full-Year and Q4 2018 Results
06 Feb 2019 07:00 AM
RNS
US FDA grants Fasenra Orphan Drug Designation
05 Feb 2019 07:05 AM
RNS
US FDA grants Breakthrough Therapy Designation
05 Feb 2019 07:00 AM
RNS
EMA grants PRIME eligibility for MEDI8897
01 Feb 2019 03:00 PM
RNS
Total Voting Rights
01 Feb 2019 01:17 PM
RNS
Forxiga receives positive EU CHMP opinion
25 Jan 2019 02:00 PM
RNS
Completion of divestment of US Synagis rights
07 Jan 2019 01:00 PM
RNS
AstraZeneca announces organisational changes
02 Jan 2019 03:00 PM
RNS
Total Voting Rights
20 Dec 2018 01:47 PM
RNS
Bevespi Aerosphere approved in the EU for COPD
20 Dec 2018 07:05 AM
RNS
Lynparza meets primary endpoint in SOLO-3 trial
20 Dec 2018 07:00 AM
RNS
Phase III ROCKIES and OLYMPUS roxadustat trials
19 Dec 2018 06:31 PM
RNS
FDA approves Lynparza as 1L maintenance therapy
18 Dec 2018 09:09 AM
RNS
Roxadustat approved in China for the treatment of
14 Dec 2018 07:00 AM
RNS
Directorate Change
07 Dec 2018 07:00 AM
RNS
Update on the Phase III EAGLE trial of Imfinzi
06 Dec 2018 07:00 AM
RNS
Divestment of rights to Covis completed

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100